Efficacy and Durability of Immune Response After Receipt of HPV Vaccines in People Living with HIV

Overview

Journal Vaccines (Basel)

Date 2023 Jun 28

PMID 37376456

Authors

Cecilia Losada

Hady Samaha

Erin M Scherer

Bahaa Kazzi

Lana Khalil

Ighovwerha Ofotokun

Nadine Rouphael

Affiliations

Soon will be listed here.

Abstract

People living with HIV (PLH) experience higher rates of HPV infection as well as an increased risk of HPV-related disease, including malignancies. Although they are considered a high-priority group for HPV vaccination, there are limited data regarding the long-term immunogenicity and efficacy of HPV vaccines in this population. Seroconversion rates and geometric mean titers elicited by vaccination are lower in PLH compared to immunocompetent participants, especially in individuals with CD4 counts below 200 cells/mm and a detectable viral load. The significance of these differences is still unclear, as a correlate of protection has not been identified. Few studies have focused on demonstrating vaccine efficacy in PLH, with variable results depending on the age at vaccination and baseline seropositivity. Although waning humoral immunity for HPV seems to be more rapid in this population, there is evidence that suggests that seropositivity lasts at least 2-4 years following vaccination. Further research is needed to determine the differences between vaccine formulations and the impact of administrating additional doses on durability of immune protection.

Citing Articles

Prevalence, Incidence and Predictors of Anal HPV Infection and HPV-Related Squamous Intraepithelial Lesions in a Cohort of People Living with HIV.

Sambo M, Bailoni A, Mariani F, Granai M, Calomino N, Mancini V Diagnostics (Basel). 2025; 15(2).

PMID: 39857082 PMC: 11763758. DOI: 10.3390/diagnostics15020198.

Atypical HPV Typing: Detection of Genital-Associated HPV Type 6 in Verruca Vulgaris of the Hands and Feet in an HIV-Positive Patient.

Achdiat P, Larasati R, Hidayah R, Avriyanti E, Usman H, Maharani R Int Med Case Rep J. 2025; 18():67-74.

PMID: 39817050 PMC: 11734615. DOI: 10.2147/IMCRJ.S494454.

Intraperitoneal delivery of cannabidiol (CBD) and Δ-tetrahydocannabinol (THC) promotes papillomavirus infections in athymic nude mice.

Brendle S, Li J, Sun D, Zhu J, Henderson-Redmond A, Morgan D Tumour Virus Res. 2024; 19():200307.

PMID: 39694192 PMC: 11731512. DOI: 10.1016/j.tvr.2024.200307.

Early adoption of innovation in HPV prevention strategies: closing the gap in cervical cancer.

Mahajan I, Kadam A, McCann L, Ghose A, Wakeham K, Dhillon N Ecancermedicalscience. 2024; 18:1762.

PMID: 39430092 PMC: 11489098. DOI: 10.3332/ecancer.2024.1762.

Cancer in People with HIV.

Odeny T, Fink V, Muchengeti M, Gopal S Infect Dis Clin North Am. 2024; 38(3):531-557.

PMID: 39111924 PMC: 11529824. DOI: 10.1016/j.idc.2024.06.007.

References

Joshi S, Anantharaman D, Muwonge R, Bhatla N, Panicker G, Butt J . Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination. Vaccine. 2022; 41(1):236-245. PMC: 9792650. DOI: 10.1016/j.vaccine.2022.11.044. View

Schiller J, Lowy D . Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J Infect Dis. 2009; 200(2):166-71. PMC: 3467007. DOI: 10.1086/599988. View

Einstein M, Takacs P, Chatterjee A, Sperling R, Chakhtoura N, Blatter M . Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial. Hum Vaccin Immunother. 2014; 10(12):3435-45. PMC: 4514070. DOI: 10.4161/hv.36121. View

Prabhu P, Carter J, Galloway D . B Cell Responses upon Human Papillomavirus (HPV) Infection and Vaccination. Vaccines (Basel). 2022; 10(6). PMC: 9229470. DOI: 10.3390/vaccines10060837. View

Villa L, Costa R, Petta C, Andrade R, Ault K, Giuliano A . Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005; 6(5):271-8. DOI: 10.1016/S1470-2045(05)70101-7. View

Denny L, Franceschi S, de Sanjose S, Heard I, Moscicki A, Palefsky J . Human papillomavirus, human immunodeficiency virus and immunosuppression. Vaccine. 2012; 30 Suppl 5:F168-74. DOI: 10.1016/j.vaccine.2012.06.045. View

Kreimer A, Sampson J, Porras C, Schiller J, Kemp T, Herrero R . Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial. J Natl Cancer Inst. 2020; 112(10):1038-1046. PMC: 7566548. DOI: 10.1093/jnci/djaa011. View

Joura E, Kjaer S, Wheeler C, Sigurdsson K, Iversen O, Hernandez-Avila M . HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine. 2008; 26(52):6844-51. DOI: 10.1016/j.vaccine.2008.09.073. View

Einstein M, Levin M, Chatterjee A, Chakhtoura N, Takacs P, Catteau G . Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study. Hum Vaccin Immunother. 2014; 10(12):3455-65. PMC: 4514093. DOI: 10.4161/hv.36117. View

10.

Weinberg A, Huang S, Moscicki A, Saah A, Levin M . Persistence of memory B-cell and T-cell responses to the quadrivalent HPV vaccine in HIV-infected children. AIDS. 2018; 32(7):851-860. PMC: 5869173. DOI: 10.1097/QAD.0000000000001773. View

11.

Fernandez-Prada M, Rodriguez-Fonseca O, Brandy-Garcia A, Alonso-Penanes P, Huerta-Gonzalez I, Fernandez-Noval F . [Use of hepatitis B AS04C adjuvanted vaccine in HIV patients]. Rev Esp Quimioter. 2018; 31(2):105-109. PMC: 6159376. View

12.

Nicoli F, Mantelli B, Gallerani E, Telatin V, Bonazzi I, Marconi P . HPV-Specific Systemic Antibody Responses and Memory B Cells are Independently Maintained up to 6 Years and in a Vaccine-Specific Manner Following Immunization with Cervarix and Gardasil in Adolescent and Young Adult Women in Vaccination Programs in.... Vaccines (Basel). 2020; 8(1). PMC: 7175219. DOI: 10.3390/vaccines8010026. View

13.

Combes J, Heard I, Poizot-Martin I, Canestri A, Lion A, Piroth L . Prevalence and Risk Factors for Anal Human Papillomavirus Infection in Human Immunodeficiency Virus-Positive Men Who Have Sex with Men. J Infect Dis. 2018; 217(10):1535-1543. DOI: 10.1093/infdis/jiy059. View

14.

Schiller J, Lowy D . Explanations for the high potency of HPV prophylactic vaccines. Vaccine. 2018; 36(32 Pt A):4768-4773. PMC: 6035892. DOI: 10.1016/j.vaccine.2017.12.079. View

15.

Clifford G, Georges D, Shiels M, Engels E, Albuquerque A, Poynten I . A meta-analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale. Int J Cancer. 2020; 148(1):38-47. PMC: 7689909. DOI: 10.1002/ijc.33185. View

16.

Levin M, Huang S, Moscicki A, Song L, Read J, Meyer W . Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine. Vaccine. 2017; 35(13):1712-1720. PMC: 5665177. DOI: 10.1016/j.vaccine.2017.02.021. View

17.

Krajden M, Cook D, Yu A, Chow R, Mei W, McNeil S . Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial. Clin Vaccine Immunol. 2011; 18(3):418-23. PMC: 3067374. DOI: 10.1128/CVI.00489-10. View

18.

Mix J, Van Dyne E, Saraiya M, Hallowell B, Thomas C . Assessing Impact of HPV Vaccination on Cervical Cancer Incidence among Women Aged 15-29 Years in the United States, 1999-2017: An Ecologic Study. Cancer Epidemiol Biomarkers Prev. 2020; 30(1):30-37. PMC: 7855406. DOI: 10.1158/1055-9965.EPI-20-0846. View

19.

Lacey C . HPV vaccination in HIV infection. Papillomavirus Res. 2019; 8:100174. PMC: 6603434. DOI: 10.1016/j.pvr.2019.100174. View

20.

Whitaker J, Rouphael N, Edupuganti S, Lai L, Mulligan M . Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1. Lancet Infect Dis. 2012; 12(12):966-76. PMC: 4141523. DOI: 10.1016/S1473-3099(12)70243-8. View